ATE537815T1 - Kristalline arzneimittelteilchen, die in einem verfahren mit kontrollierter abscheidung (rekristallisation) hergestellt werden - Google Patents
Kristalline arzneimittelteilchen, die in einem verfahren mit kontrollierter abscheidung (rekristallisation) hergestellt werdenInfo
- Publication number
- ATE537815T1 ATE537815T1 AT03766858T AT03766858T ATE537815T1 AT E537815 T1 ATE537815 T1 AT E537815T1 AT 03766858 T AT03766858 T AT 03766858T AT 03766858 T AT03766858 T AT 03766858T AT E537815 T1 ATE537815 T1 AT E537815T1
- Authority
- AT
- Austria
- Prior art keywords
- crystalline
- particles
- recristallization
- particles produced
- controlled deposition
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 230000008021 deposition Effects 0.000 title 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 229940088679 drug related substance Drugs 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/213,907 US20040028746A1 (en) | 2002-08-06 | 2002-08-06 | Crystalline drug particles prepared using a controlled precipitation (recrystallization) process |
| PCT/US2003/021882 WO2004012710A1 (en) | 2002-08-06 | 2003-07-14 | Crystalline drug particles prepared using a controlled precipitation (recrystallization) process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE537815T1 true ATE537815T1 (de) | 2012-01-15 |
Family
ID=31494557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03766858T ATE537815T1 (de) | 2002-08-06 | 2003-07-14 | Kristalline arzneimittelteilchen, die in einem verfahren mit kontrollierter abscheidung (rekristallisation) hergestellt werden |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040028746A1 (enExample) |
| EP (1) | EP1545463B1 (enExample) |
| JP (1) | JP2005536525A (enExample) |
| CN (1) | CN100356905C (enExample) |
| AT (1) | ATE537815T1 (enExample) |
| AU (1) | AU2003249195A1 (enExample) |
| CA (1) | CA2494277A1 (enExample) |
| WO (1) | WO2004012710A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| CN114394909B (zh) * | 2021-12-31 | 2024-06-07 | 大连新阳光材料科技有限公司 | 对氨基苯甲酸微粉的制备方法 |
| CN120603631A (zh) | 2023-01-18 | 2025-09-05 | 纳米形态芬兰有限公司 | 活性药物成分的结晶的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| SE9101090D0 (sv) * | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
| US5716642A (en) * | 1995-01-10 | 1998-02-10 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents |
| SE9501384D0 (sv) * | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| US5715642A (en) * | 1995-08-16 | 1998-02-10 | Steel Framing Supply | Steel-frame system and member |
| US6287693B1 (en) * | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| US6869617B2 (en) * | 2000-12-22 | 2005-03-22 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US20030152500A1 (en) * | 2001-10-17 | 2003-08-14 | Dalziel Sean Mark | Rotor-stator apparatus and process for the formation of particles |
-
2002
- 2002-08-06 US US10/213,907 patent/US20040028746A1/en not_active Abandoned
-
2003
- 2003-07-14 CA CA002494277A patent/CA2494277A1/en not_active Abandoned
- 2003-07-14 JP JP2004526104A patent/JP2005536525A/ja active Pending
- 2003-07-14 CN CNB038187817A patent/CN100356905C/zh not_active Expired - Fee Related
- 2003-07-14 EP EP03766858A patent/EP1545463B1/en not_active Expired - Lifetime
- 2003-07-14 AU AU2003249195A patent/AU2003249195A1/en not_active Abandoned
- 2003-07-14 AT AT03766858T patent/ATE537815T1/de active
- 2003-07-14 WO PCT/US2003/021882 patent/WO2004012710A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1545463A1 (en) | 2005-06-29 |
| CN100356905C (zh) | 2007-12-26 |
| CN1674872A (zh) | 2005-09-28 |
| US20040028746A1 (en) | 2004-02-12 |
| CA2494277A1 (en) | 2004-02-12 |
| WO2004012710A8 (en) | 2005-06-30 |
| AU2003249195A1 (en) | 2004-02-23 |
| WO2004012710A1 (en) | 2004-02-12 |
| EP1545463B1 (en) | 2011-12-21 |
| JP2005536525A (ja) | 2005-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201909267T4 (tr) | Sinakalset HCl içeren hızlı çözünme formülasyonu. | |
| DE69917883D1 (de) | Phospholipid-beschichtete mikrokristalle für die kontrollierte abgabe von pharmakologisch aktiven verbindungen und verfahren zu deren herstellung und verwendung | |
| DE69429078D1 (de) | Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung | |
| DE60229059D1 (de) | Proteomimetische verbindungen und verfahren | |
| ATE517610T1 (de) | Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreinchungsform | |
| ATE489365T1 (de) | Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-6,6-dimethyl-3-azabicycloä3,1,0 ühexan-2-carboxylaten oder salzen davon | |
| DE60127977D1 (de) | Verfahren zur herstellung von zähen, wärmehärtenden gegenständen und die wärmehärtenden gegenstände so hergestellt | |
| DE60204322D1 (de) | Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen | |
| BR0316375A (pt) | Diazinopirimidinas | |
| DE60317562D1 (de) | Benzofuranderivate,verfahren zu deren herstellung und zwischenprodukte davon | |
| BRPI0113286B8 (pt) | pirazóis substituídos e composição farmacêutica compreendendo os mesmos. | |
| ATE249435T1 (de) | Neue kristalline form gamma des tert-butylamin salzes von perindopril, verfahren zu deren herstellung und dieses enthaltende arzneimittel | |
| EA201000643A1 (ru) | Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе | |
| ATE206119T1 (de) | Thiacyclische piperidinylderivate | |
| ATE330943T1 (de) | Herstellungsverfahren von huperzine a und deren analogen und verbindungen nützlich dazu | |
| HUP9802121A2 (hu) | Imidazolinszármazékok, eljárás előállításukra és e vegyületeket tartalmazó gyógyszerkészítmények | |
| DE50112128D1 (de) | Retardpartikeldispersion | |
| DE60108489D1 (de) | Kombinationstherapien mit gefässschädigender aktivität | |
| ATE209905T1 (de) | Pharmazeutische zusammensetzungen in form von polymeren mikropartikeln erhalten durch extrusion und bildung von kügelchen | |
| HUP0103203A2 (hu) | Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
| MX2023014722A (es) | Forma cristalina de tolebrutinib y método de preparación y su uso. | |
| DE69809284D1 (de) | Immunomodulator mit anti-mikrobakteriellen und anti-mykobakteriellen eigenschaften, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen zur behandlung von mykobakteriosen sowie von chronischen und nicht-spezifischen lungenzuständen, sexuell übertragbaren krankheiten und den daraus resultierenden immunschwächen | |
| DE69924304D1 (de) | N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin | |
| ATE316086T1 (de) | Clathrat von azithromycin-hydrat mit 1,2- propylenglykol, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zusammensetzung | |
| ATE537815T1 (de) | Kristalline arzneimittelteilchen, die in einem verfahren mit kontrollierter abscheidung (rekristallisation) hergestellt werden |